Alzheimer’s disease affects more than 35 million people, a number that is expected to increase in the coming years. Currently, Alzheimer’s diagnoses rely on clinical neuropathologic assessment of amyloid-β (Aβ) peptide aggregates (plaques) and neurofibrillary tangles. But in ACS Central Science, researchers reveal that an enzyme already implicated in a host of neural disorders could someday serve as a biomarker.
from Dementia Big http://ift.tt/2gXVguN via alcoholic dementia
http://ift.tt/2ggAQt0
No comments:
Post a Comment